Ovarian Cancer
European Commission grants orphan drug designation in for OvaRex MAb
Published in Cancer Weekly, September 17th, 2002
Orphan drug designation makes the product eligible for orphan drug exclusivity. If a product which has an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product will be entitled to orphan drug exclusivity.
This exclusivity means that applications to market the same product for the same use may not be approved by the European Commission, except in very limited circumstances, for a period of up to 10 years and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2002-09-17)
More Articles from Cancer Weekly
- Cancer Therapy
Technique to induce cancer cells to 'commit suicide' developed by Hebrew University scientists - Vaccine Prophylaxis
Measles, varicella, and influenza immunizations recommended for adult cancer patients - Breast Cancer
Reactive nitrogen species foster vascularity of breast tumors - Cancer Therapy
Anti-inflammatory drug reduces growth of cancerous tumors in rats - Cancer Therapy
New drug possible from compound found in common food. - Complementary and Alternative Medicine
Cancer patients can be endangered by CAM 'cures' on the web - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
